Protagonist Therapeutics (PTGX) Operating Leases (2019 - 2026)

Protagonist Therapeutics (PTGX) has 8 years of Operating Leases data on file, last reported at $7.4 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 24.05% year-over-year to $7.4 million; the trailing twelve-month figure through Mar 2026 stood at $7.4 million (down 24.05% YoY), and the FY2025 full-year result was $8.0 million, down 22.36% from the prior year.
• Operating Leases retreated to $7.4 million in Q1 2026, from $8.0 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $11.0 million in Q2 2024 to a low of $462000.0 in Q1 2023.
• A 5-year average of $6.5 million and a median of $8.0 million in 2025 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases tumbled 84.91% in 2023 and declined 17.0% in 2025, its largest moves.
• Tracing PTGX's Operating Leases over 5 years: stood at $1.1 million in 2022, then tumbled by 59.51% to $462000.0 in 2023, then jumped by 2141.56% to $10.4 million in 2024, then dropped by 22.36% to $8.0 million in 2025, then decreased by 7.5% to $7.4 million in 2026.
• Business Quant data shows PTGX's Operating Leases at $7.4 million in Q1 2026, $8.0 million in Q4 2025, and $8.5 million in Q3 2025.